Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transarterial Radioembolisation with Y90 Resin Microspheres and the Effect of Reimbursement Criteria in France: Final Results of the CIRT-FR Prospective Observational Study.

Cardiovascular and interventional radiology·2025
Same author

Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel-Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study.

Genetics in medicine : official journal of the American College of Medical Genetics·2021
Same author

The infragluteal fold: An appraisal by MRI combined with an anatomic study.

Surgical and radiologic anatomy : SRA·2021
Same author

Computer-aided diagnosis system for characterizing ISUP grade≥2 prostate cancers at multiparametric MRI: A cross-vendor evaluation.

Diagnostic and interventional imaging·2019
Same author

Endovascular stenting for chronic femoro-iliac venous obstructive disease: Clinical efficacy and short-term outcomes.

Diagnostic and interventional imaging·2019
Same author

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2017

Related Experiment Video

Updated: May 30, 2026

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Interventional radiology for hepatocellular carcinoma.

R Loffroy1

  • 1Department of Vascular and Interventional Radiology, University of Dijon School of Medicine, Dijon, France. romaric.loffroy@gmail.com

Minerva Gastroenterologica E Dietologica
|July 20, 2011
PubMed
Summary

Locoregional interventional therapies offer crucial management options for unresectable hepatocellular carcinoma (HCC). This review details catheter-based and ablative approaches for treating this common liver cancer.

More Related Videos

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Experiment Videos

Last Updated: May 30, 2026

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Area of Science:

  • Oncology
  • Interventional Radiology
  • Hepatology

Background:

  • Hepatocellular carcinoma (HCC) is a prevalent primary malignant liver tumor globally.
  • Surgical options like resection and transplantation are optimal but only feasible for 20% of patients.
  • The majority of non-surgically eligible HCC patients require locoregional interventional management.

Purpose of the Study:

  • To review current interventional radiology approaches for unresectable HCC.
  • To provide an evidence-based overview of available locoregional therapies.
  • To discuss the advantages and drawbacks of various interventional methods.

Main Methods:

  • Review of catheter-based therapies including embolotherapy (TACE, bland embolization, TAI, DEB-TACE) and radiotherapy (radioembolization, I-131 lipiodol).
  • Review of percutaneous ablative therapies including chemical (ethanol, acetic acid) and thermal (RFA, LITT, MWA, cryoablation, HIFU) methods.
  • Evidence-based analysis of the current role of interventional radiology in unresectable HCC management.

Main Results:

  • Significant technical advancements have expanded the range of combined interventional therapies for HCC.
  • Catheter-based treatments offer targeted delivery of chemotherapy or radiation.
  • Ablative therapies provide localized destruction of tumor tissue.
  • Each interventional method presents unique benefits and limitations.

Conclusions:

  • Interventional radiology plays a vital role in managing unresectable HCC.
  • A diverse array of locoregional therapies is available, with ongoing technical development.
  • The selection of treatment depends on individual patient factors and tumor characteristics.
  • Combined interventional approaches are increasingly utilized to improve outcomes.